Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
Recruiting · NCT05345860 · Registry updated 2022-04-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2022-04-26 | NCT05345860 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Huanxing Cancer Hospital | Beijing | China | 1 |
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing | China | 41 |
| Cancer Hospital, Chinese Academy of Medical Sciences, Hebei Center | Langfang | China | 1 |